CA2288821C - Modulation of human mast cell activation - Google Patents

Modulation of human mast cell activation Download PDF

Info

Publication number
CA2288821C
CA2288821C CA002288821A CA2288821A CA2288821C CA 2288821 C CA2288821 C CA 2288821C CA 002288821 A CA002288821 A CA 002288821A CA 2288821 A CA2288821 A CA 2288821A CA 2288821 C CA2288821 C CA 2288821C
Authority
CA
Canada
Prior art keywords
purinoceptor
mast cells
atp
ligand
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002288821A
Other languages
English (en)
French (fr)
Other versions
CA2288821A1 (en
Inventor
Amir Pelleg
Edward S. Schulman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duska Scientific Co
Original Assignee
Duska Scientific Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duska Scientific Co filed Critical Duska Scientific Co
Publication of CA2288821A1 publication Critical patent/CA2288821A1/en
Application granted granted Critical
Publication of CA2288821C publication Critical patent/CA2288821C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
CA002288821A 1997-03-25 1998-03-24 Modulation of human mast cell activation Expired - Fee Related CA2288821C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4146197P 1997-03-25 1997-03-25
US60/041,461 1997-03-25
PCT/US1998/005922 WO1998042353A1 (en) 1997-03-25 1998-03-24 Modulation of human mast cell activation

Publications (2)

Publication Number Publication Date
CA2288821A1 CA2288821A1 (en) 1998-10-01
CA2288821C true CA2288821C (en) 2008-10-14

Family

ID=21916643

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002288821A Expired - Fee Related CA2288821C (en) 1997-03-25 1998-03-24 Modulation of human mast cell activation

Country Status (9)

Country Link
US (2) US6372724B1 (cg-RX-API-DMAC7.html)
EP (1) EP1011686B9 (cg-RX-API-DMAC7.html)
JP (1) JP2001518118A (cg-RX-API-DMAC7.html)
AT (1) ATE470441T1 (cg-RX-API-DMAC7.html)
AU (1) AU741713B2 (cg-RX-API-DMAC7.html)
CA (1) CA2288821C (cg-RX-API-DMAC7.html)
DE (1) DE69841711D1 (cg-RX-API-DMAC7.html)
DK (1) DK1011686T3 (cg-RX-API-DMAC7.html)
WO (1) WO1998042353A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2288821C (en) * 1997-03-25 2008-10-14 Allegheny University Of The Health Sciences Modulation of human mast cell activation
DK1187617T3 (da) * 1999-06-18 2004-04-13 Alcon Mfg Ltd Fremgangsmåde til at vælge koncentrationen af et amfipatisk antihistaminlægemiddel ved at bestemme lægemidlets overfladeaktivitetsmåltal
GB9916757D0 (en) 1999-07-17 1999-09-15 Glaxo Group Ltd Method
EP1269198A2 (en) * 2000-03-23 2003-01-02 Novartis AG Identification of mast/basophil activation inhibitors
US20040072865A1 (en) * 2001-01-15 2004-04-15 Bouillot Anne Marie Jeanne Aryl piperidine derivatives as inducers of ldl-receptor expression
JP2004520347A (ja) * 2001-01-15 2004-07-08 グラクソ グループ リミテッド Ldl−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
EP1351937A1 (en) * 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
MXPA04004215A (es) * 2001-11-06 2004-07-08 Inspire Pharmaceuticals Inc Metodo para el tratamiento o la prevencion de enfermedades inflamatorias.
WO2003070902A2 (en) * 2002-02-20 2003-08-28 Incyte Corporation Receptors and membrane-associated proteins
US20070276126A1 (en) * 2002-08-13 2007-11-29 Incyte Corporation Cell adhesion and extracellular matrix proteins
US20070219353A1 (en) * 2002-09-03 2007-09-20 Incyte Corporation Immune Response Associated Proteins
AU2003279829A1 (en) * 2002-10-04 2004-05-04 Incyte Corp Protein modification and maintenance molecules
AU2003300785A1 (en) * 2002-11-12 2004-06-03 Incyte Corporation Carbohydrate-associated proteins
AU2003295462A1 (en) * 2002-11-13 2004-06-03 Incyte Corporation Lipid-associated proteins
AU2003302234A1 (en) * 2002-11-26 2004-06-18 Incyte Corporation Immune response associated proteins
WO2004098539A2 (en) 2003-04-30 2004-11-18 Incyte Corporation Kinases and phosphatases
WO2006012639A2 (en) * 2004-07-22 2006-02-02 Duska Scientific Co. Method of diagnosing, monitoring and treating pulmonary diseases
EP1910535B1 (en) 2005-06-24 2016-08-17 The Walter And Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
CA2680801A1 (en) * 2007-03-14 2008-09-18 Sierra Molecular Corporation Compositions, systems, and methods for preservation and/or stabilizationof a cell and/or macromolecule
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
US10107795B2 (en) 2012-10-25 2018-10-23 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for the prevention and treatment of diet-induced obesity
US10614684B2 (en) 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53148539A (en) * 1977-05-30 1978-12-25 Fujisawa Pharmaceut Co Ltd Antiallergic agnet
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
EP0760850A1 (en) * 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5874420A (en) 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
CA2288821C (en) * 1997-03-25 2008-10-14 Allegheny University Of The Health Sciences Modulation of human mast cell activation

Also Published As

Publication number Publication date
ATE470441T1 (de) 2010-06-15
WO1998042353A1 (en) 1998-10-01
US6465441B2 (en) 2002-10-15
US6372724B1 (en) 2002-04-16
EP1011686B9 (en) 2011-02-09
EP1011686B1 (en) 2010-06-09
JP2001518118A (ja) 2001-10-09
EP1011686A4 (en) 2003-03-19
CA2288821A1 (en) 1998-10-01
AU7098598A (en) 1998-10-20
DE69841711D1 (de) 2010-07-22
AU741713B2 (en) 2001-12-06
DK1011686T3 (da) 2010-10-11
US20020055515A1 (en) 2002-05-09
EP1011686A1 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
EP1011686B1 (en) Modulation of human mast cell activation
Maybaum et al. Regulation of RNA-and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells
FAIRBANKS et al. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?
Partida-Sánchez et al. Innate immunity is regulated by CD38, an ecto-enzyme with ADP-ribosyl cyclase activity
Wilson et al. Adenosine receptors and asthma
Choukèr et al. Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway
Davoine et al. Expression of FcγRIII (CD16) on human peripheral blood eosinophils increases in allergic conditions
Ezeamuzie Involvement of A3 receptors in the potentiation by adenosine of the inhibitory effect of theophylline on human eosinophil degranulation: possible novel mechanism of the anti-inflammatory action of theophylline
Pelleg et al. Adenosine 5-triphosphate axis in obstructive airway diseases
Moqbel et al. Enhancement of leukocyte cytotoxicity after exercise-induced asthma
Michael et al. Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations
Gabriella Matera et al. New treatments for COPD in the elderly
Arm et al. Expression of complement receptors type 1 (CR1) and type 3 (CR3) on circulating granulocytes in experimentally provoked asthma
Agarwal et al. Thymidine and zidovudine metabolism in chronically zidovudine-exposed cells in vitro
Kaelin et al. Influence of ethanol on human T-lymphocyte migration
Wehlin et al. Reduced intracellular oxygen radical production in whole blood leukocytes from COPD patients and asymptomatic smokers
Schwartz Cellular Inflammation in Asthma: Neutral Proteases of Mast Cells1, 2
Bourne Leukocyte cyclic AMP: pharmacological regulation and possible physiological implications
Suwaki et al. Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug
Walker Effects of adenosine on guinea pig pulmonary eosinophils
WO1995010287A1 (en) Substituted purine nucleoside analogs and method for treating endotoxin shock
Tedeschi et al. Inhibition of basophil histamine release by tyrosine kinase and phosphatidylinositol 3-kinase inhibitors
Abrams et al. Cytotoxic T lymphocyte-induced loss of target cell adhesion and lysis involve common and separate signaling pathways.
Benyon et al. IgE-dependent activation of human lung mast cells is not associated with increased phospholipid methylation.
Laubinger et al. Evidence for a G protein-coupled diadenosine-5′, 5‴-P1, P4-tetraphosphate (Ap4A) receptor binding site in lung membranes from rat

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130325